PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2820746-7 1987 Tamoxifen (TMX) and its metabolites dihydroxy (di-OH-TMX) and 4-hydroxytamoxifen (4-OH-TMX) inhibited PRL in a dose-dependent manner. Tamoxifen 0-9 prolactin Rattus norvegicus 102-105 2583366-0 1989 Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Tamoxifen 64-73 prolactin Rattus norvegicus 51-60 2583366-3 1989 TAM and TACE acted as partial agonists on PRL and uterine weight induction. Tamoxifen 0-3 prolactin Rattus norvegicus 42-45 2820746-7 1987 Tamoxifen (TMX) and its metabolites dihydroxy (di-OH-TMX) and 4-hydroxytamoxifen (4-OH-TMX) inhibited PRL in a dose-dependent manner. Tamoxifen 11-14 prolactin Rattus norvegicus 102-105 2820746-8 1987 The PRL release inhibiting effect of 4-OH-TMX was 100 times more potent that those of TMX and di-OH-TMX, which were similar in their effect. Tamoxifen 42-45 prolactin Rattus norvegicus 4-7 2820746-10 1987 Both "endogenous" (catecholestrogens) and "exogenous" (tamoxifen and its metabolites) antiestrogens and very high concentrations of estradiol directly inhibit PRL secretion by cultured pituitary tumor cells. Tamoxifen 55-64 prolactin Rattus norvegicus 159-162 3822918-0 1987 Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma. Tamoxifen 47-56 prolactin Rattus norvegicus 8-17 3822918-1 1987 Tamoxifen (TAM) has previously been shown to inhibit growth of the Dunning R3327 rat prostate adenocarcinoma and to elevate serum prolactin levels. Tamoxifen 0-9 prolactin Rattus norvegicus 130-139 3822918-1 1987 Tamoxifen (TAM) has previously been shown to inhibit growth of the Dunning R3327 rat prostate adenocarcinoma and to elevate serum prolactin levels. Tamoxifen 11-14 prolactin Rattus norvegicus 130-139 3822918-2 1987 The purpose of this study was to determine the role of prolactin in modulating the effects of tamoxifen on growth of the R3327 prostatic adenocarcinoma. Tamoxifen 94-103 prolactin Rattus norvegicus 55-64 3822918-10 1987 In contrast, the stimulatory effect of TAM in castrate rats appears to result directly from an estrogen-like action, which can directly enhance prostatic tumor growth in the presence of low levels of circulating androgens; this stimulatory effect of TAM is more pronounced when prolactin levels are suppressed by CB-154. Tamoxifen 39-42 prolactin Rattus norvegicus 278-287 6323151-3 1983 Combined administration of ovine PRL and tamoxifen attenuated the inhibitory action of tamoxifen on tumor growth. Tamoxifen 87-96 prolactin Rattus norvegicus 33-36 3758472-1 1986 The antiestrogens LY117018 and tamoxifen increased prolactin production about 4-fold and cell number about 2.5-fold in the pituitary tumor cell line, GH4C1; these increases were 30-40% of the maximal effects of estradiol. Tamoxifen 31-40 prolactin Rattus norvegicus 51-60 3758472-4 1986 Tamoxifen and LY117018 increased the amount of prolactin mRNA per cell. Tamoxifen 0-9 prolactin Rattus norvegicus 47-56 6323151-8 1983 Specific PRL binding to the liver was significantly reduced by treatment with bromocriptine, tamoxifen and tamoxifen plus ovine PRL, whereas PRL receptors in mammary tumor were not influenced by these drugs. Tamoxifen 93-102 prolactin Rattus norvegicus 9-12 6323151-8 1983 Specific PRL binding to the liver was significantly reduced by treatment with bromocriptine, tamoxifen and tamoxifen plus ovine PRL, whereas PRL receptors in mammary tumor were not influenced by these drugs. Tamoxifen 107-116 prolactin Rattus norvegicus 9-12 6323151-9 1983 These results suggest that PRL may stimulate DMBA-induced tumor growth independently of ER and that a part of the inhibiting effect of tamoxifen on tumor growth may be explained by the decreased PRL secretion. Tamoxifen 135-144 prolactin Rattus norvegicus 195-198 3771192-2 1986 The immunocompetence of tamoxifen citrate- and pergolide mesylate-suppressed animals could be fully restored by additional treatment with prolactin or growth hormone. Tamoxifen 24-41 prolactin Rattus norvegicus 138-147 3087134-0 1986 The effect of oestriol and tamoxifen on oestradiol induced prolactin secretion in anaesthetised rats. Tamoxifen 27-36 prolactin Rattus norvegicus 59-68 6702402-6 1984 Immunoperoxidase staining of Prl cells in the pars distalis of the hypophysis indicated that adaptive hypertrophy and signs of hypersecretion after E2B were abolished by TAM 5 mg/kg/d. Tamoxifen 170-173 prolactin Rattus norvegicus 29-32 6702402-11 1984 Secretory activity of Prl cells was reduced by TAM 0.5 mg/kg/d. Tamoxifen 47-50 prolactin Rattus norvegicus 22-25 6323151-4 1983 Serum PRL levels were decreased by both bromocriptine and tamoxifen administration. Tamoxifen 58-67 prolactin Rattus norvegicus 6-9 6323151-7 1983 Combined administration of ovine PRL with tamoxifen attenuated the inhibition of PgR induced by tamoxifen alone, while ER remained undetectable. Tamoxifen 96-105 prolactin Rattus norvegicus 33-36 7078703-2 1982 We previously showed that the antiestrogenic drug tamoxifen inhibited hormone release from transplantable PRL-secreting pituitary tumors in rats. Tamoxifen 50-59 prolactin Rattus norvegicus 106-109 6854193-1 1983 The antioestrogenic drug tamoxifen was administered to rats bearing transplanted prolactin-secreting tumours derived from spontaneously occurring pituitary adenomas in Wistar-Furth rats. Tamoxifen 25-34 prolactin Rattus norvegicus 81-90 6854193-5 1983 Tamoxifen increased prolactin secretion by tumour cells in vitro but did not affect DNA synthesis. Tamoxifen 0-9 prolactin Rattus norvegicus 20-29 6854193-6 1983 Normal rats responded to tamoxifen with a moderate increase in plasma prolactin concentrations and there was no change in pituitary DNA synthesis. Tamoxifen 25-34 prolactin Rattus norvegicus 70-79 815505-2 1976 Tamoxifen (50, 200 and 800 mug daily), administered to ovariectomized rats, produced significant (P less than 0 X 05) decreases in oestrogen-stimulated prolactin levels but was unable to reduce prolactin to control values. Tamoxifen 0-9 prolactin Rattus norvegicus 152-161 7306549-4 1981 The antiestrogen tamoxifen (trans-1-(p-beta-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene) was demonstrated to inhibit estradiol-stimulated prolactin syntheses. Tamoxifen 17-26 prolactin Rattus norvegicus 143-152 908269-3 1977 Unexpectedly, the estrogen antagonists enclomiphene, CI-628, tamoxifen, and Lilly 88751 caused increases in both prolactin and growth hormone synthesis at concentrations of about 10(-7) to 10(-6)M after one week of treatment. Tamoxifen 61-70 prolactin Rattus norvegicus 113-122 7204884-1 1980 Tamoxifen has recently been shown to suppress the growth and secretion of prolactin (PRL)-secreting pituitary tumors in rats. Tamoxifen 0-9 prolactin Rattus norvegicus 74-83 7204884-1 1980 Tamoxifen has recently been shown to suppress the growth and secretion of prolactin (PRL)-secreting pituitary tumors in rats. Tamoxifen 0-9 prolactin Rattus norvegicus 85-88 7430882-0 1980 Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. Tamoxifen 0-9 prolactin Rattus norvegicus 40-49 7430882-0 1980 Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. Tamoxifen 0-9 prolactin Rattus norvegicus 89-98 7430882-4 1980 These effects of tamoxifen on tumour growth were accompanied by a decrease in the level of prolactin in the circulation, if the treatment was started at an early stage of tumour development and if the high dose of tamoxifen was administered. Tamoxifen 17-26 prolactin Rattus norvegicus 91-100 7430882-4 1980 These effects of tamoxifen on tumour growth were accompanied by a decrease in the level of prolactin in the circulation, if the treatment was started at an early stage of tumour development and if the high dose of tamoxifen was administered. Tamoxifen 214-223 prolactin Rattus norvegicus 91-100 7430882-7 1980 Despite the inhibitory effect of tamoxifen on both tumour size and plasma levels of prolactin, the ability of the pituitary glands of these animals to synthesize prolactin remained suppressed. Tamoxifen 33-42 prolactin Rattus norvegicus 84-93 7430882-8 1980 It was concluded that tamoxifen has a dual effect on this model of a transplantable pituitary tumour that secretes prolactin in the rat; it prevents and/or inhibits tumour growth and it has an inhibitory effect on the synthesis of prolactin by the pituitary gland. Tamoxifen 22-31 prolactin Rattus norvegicus 115-124 7430882-8 1980 It was concluded that tamoxifen has a dual effect on this model of a transplantable pituitary tumour that secretes prolactin in the rat; it prevents and/or inhibits tumour growth and it has an inhibitory effect on the synthesis of prolactin by the pituitary gland. Tamoxifen 22-31 prolactin Rattus norvegicus 231-240 27696120-4 2016 Tamoxifen administration partially prevented PRL release induced by the combined treatment. Tamoxifen 0-9 prolactin Rattus norvegicus 45-48 33491243-7 2021 However, prolactin level was markedly decreased after pretreatment of CGA in TAM-treated rats. Tamoxifen 77-80 prolactin Rattus norvegicus 9-18 9657197-10 1998 CONCLUSION: Tamoxifen, an antiestrogen, exerts its antitumor effect on GH3 cells in two ways: by suppression of cell growth and by causing a decrease in PRL. Tamoxifen 12-21 prolactin Rattus norvegicus 153-156 25665530-6 2015 Tamoxifen reduced the plasma LH and PRL levels and decreased the nNOS mRNA and pnNOS expression in the MPOA. Tamoxifen 0-9 prolactin Rattus norvegicus 36-39 16595727-0 2006 Estradiol and its membrane-impermeable conjugate estradiol-BSA inhibit tamoxifen-stimulated prolactin secretion in incubated rat pituitaries. Tamoxifen 71-80 prolactin Rattus norvegicus 92-101 16595727-1 2006 In the absence of estrogen (E), the selective E receptor modulator tamoxifen (TX) has two agonist effects in the rat pituitary: induction of progesterone receptor (PR)-dependent GnRH self-priming in the gonadotrope, and stimulation of prolactin (PRL) secretion in the lactotrope. Tamoxifen 67-76 prolactin Rattus norvegicus 235-244 16595727-1 2006 In the absence of estrogen (E), the selective E receptor modulator tamoxifen (TX) has two agonist effects in the rat pituitary: induction of progesterone receptor (PR)-dependent GnRH self-priming in the gonadotrope, and stimulation of prolactin (PRL) secretion in the lactotrope. Tamoxifen 67-76 prolactin Rattus norvegicus 246-249 15993477-0 2005 Effects of estrogen and tamoxifen on the ultrastructural characteristics of female rat prolactin cells as evaluated by immunogold technique. Tamoxifen 24-33 prolactin Rattus norvegicus 87-96 15993477-2 2005 This study was planned to investigate the effects of estrogen and tamoxifen at immunohistochemical and immunoelectron microscopic levels on PRL cells of female rat pituitary. Tamoxifen 66-75 prolactin Rattus norvegicus 140-143 15993477-11 2005 At the ultrastructural level, in the tamoxifen treated group, PRL-producing cells contained both immunopositive and immunonegative secretory granules. Tamoxifen 37-46 prolactin Rattus norvegicus 62-65 24905513-9 2014 Tamoxifen on days 14 and 15 of pregnancy completely blocked Mp and NAL effects on prolactin release at late pregnancy. Tamoxifen 0-9 prolactin Rattus norvegicus 82-91 10904132-5 2000 However, treatment with tamoxifen elevated PRL in all groups. Tamoxifen 24-33 prolactin Rattus norvegicus 43-46 1584221-2 1992 After 5 days of treatment with either TAM (1.0 microM) or E2 (1.0 nM), the level of PRL mRNA was markedly increased when measured by the cytosolic dot blot procedure. Tamoxifen 38-41 prolactin Rattus norvegicus 84-87 9390012-14 1997 When tamoxifen was administered on days 14 and 15 of pregnancy, the high serum prolactin levels on day 19 induced by treatment with RU-486 and naloxone were significantly reduced. Tamoxifen 5-14 prolactin Rattus norvegicus 79-88 7581021-4 1995 Serum prolactin levels were suppressed to the same extent in the TAM- and 1.0 mg NA-treated groups compared with rats given estrogen alone (2.3 +/- 0.3 and 5.6 +/- 1.5 ng/ml for TAM and NA groups vs 39.7 +/- 3.6 ng/ml for VE groups, P < 0.05). Tamoxifen 65-68 prolactin Rattus norvegicus 6-15 7581021-7 1995 Although no prolactin immunostaining was detected in the uterus of rats treated with estradiol, uterine immunoreactive prolactin was identified in those treated with NA, TAM or both. Tamoxifen 170-173 prolactin Rattus norvegicus 119-128 8740191-9 1996 Tamoxifen associated to subacute period of estrogen administration resulted in a significant reduction of serum prolactin levels and pituitary weight (p < 0.05). Tamoxifen 0-9 prolactin Rattus norvegicus 112-121 8740191-12 1996 In conclusion, the results of the present paper showed that tamoxifen reduced estrogen-stimulated prolactin levels in some, but not in other hormonal conditions and that these effects were not mediated by an inhibition of lactotroph cell growth. Tamoxifen 60-69 prolactin Rattus norvegicus 98-107 8476783-7 1993 Serum prolactin (PRL) levels, assayed 4 h after the last dose, were unchanged in the group treated with the combination, whereas tamoxifen alone caused a slight increase of serum PRL. Tamoxifen 129-138 prolactin Rattus norvegicus 179-182 1584221-11 1992 TAM at concentrations ranging from 10(-8)-10(-6) M was effective in inducing PRL mRNA, but at none of the tested concentrations was TAM effective in stimulating cell proliferation or inducing PR. Tamoxifen 0-3 prolactin Rattus norvegicus 77-80